期刊
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY
卷 62, 期 -, 页码 483-507出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-pharmtox-052220-021800
关键词
endocannabinoid; FAAH; DGL; MGL; NAPE-PLD; THC
资金
- National Institutes of Health [P50DA044118-01A1]
Endocannabinoids are lipid-derived messengers that regulate various physiological processes in mammals. Dysfunctions in their activity have been linked to diseases, leading to interest in the endocannabinoid system as a potential source of therapeutic drugs. This review provides an overview of endocannabinoid formation, deactivation, and biotransformation, and discusses the properties and therapeutic potential of pharmacological agents that interfere with these processes.
The endocannabinoids are lipid-derived messengers that play a diversity of regulatory roles in mammalian physiology. Dysfunctions in their activity have been implicated in various disease conditions, attracting attention to the endocannabinoid system as a possible source of therapeutic drugs. This signaling complex has three components: the endogenous ligands, anandamide and 2-arachidonoyl-sn-glycerol (2-AG); a set of enzymes and transporters that generate, eliminate, or modify such ligands; and selective cell surface receptors that mediate their biological actions. We provide an overview of endocannabinoid formation, deactivation, and biotransformation and outline the properties and therapeutic potential of pharmacological agents that interfere with those processes. We describe small-molecule inhibitors that target endocannabinoid-producing enzymes, carrier proteins that transport the endocannabinoids into cells, and intracellular endocannabinoid-metabolizing enzymes. We briefly discuss selected agents that simultaneously interfere with components of the endocannabinoid system and with other functionally related signaling pathways.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据